Skip to main content

ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention.

Publication ,  Journal Article
Baker, JC; Ostrander, JH; Lem, S; Broadwater, G; Bean, GR; D'Amato, NC; Goldenberg, VK; Rowell, C; Ibarra-Drendall, C; Grant, T; Pilie, PG ...
Published in: Cancer Epidemiol Biomarkers Prev
August 2008

PURPOSE: Currently, we lack biomarkers to predict whether high-risk women with mammary atypia will respond to tamoxifen chemoprevention. EXPERIMENTAL DESIGN: Thirty-four women with cytologic mammary atypia from the Duke University High-Risk clinic were offered tamoxifen chemoprevention. We tested whether ESR1 promoter hypermethylation and/or estrogen receptor (ER) protein expression by immunohistochemistry predicted persistent atypia in 18 women who were treated with tamoxifen for 12 months and in 16 untreated controls. RESULTS: We observed a statistically significant decrease in the Masood score of women on tamoxifen chemoprevention for 12 months compared with control women. This was a significant interaction effect of time (0, 6, and 12 months) and treatment group (tamoxifen versus control) P = 0.0007. However, neither ESR1 promoter hypermethylation nor low ER expression predicted persistent atypia in Random Periareolar Fine Needle Aspiration after 12 months tamoxifen prevention. CONCLUSIONS: Results from this single institution pilot study provide evidence that, unlike for invasive breast cancer, ESR1 promoter hypermethylation and/or low ER expression is not a reliable marker of tamoxifen-resistant atypia.

Duke Scholars

Published In

Cancer Epidemiol Biomarkers Prev

DOI

ISSN

1055-9965

Publication Date

August 2008

Volume

17

Issue

8

Start / End Page

1884 / 1890

Location

United States

Related Subject Headings

  • Time Factors
  • Tamoxifen
  • Promoter Regions, Genetic
  • Predictive Value of Tests
  • Polymerase Chain Reaction
  • Pilot Projects
  • Middle Aged
  • Immunohistochemistry
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Baker, J. C., Ostrander, J. H., Lem, S., Broadwater, G., Bean, G. R., D’Amato, N. C., … Seewaldt, V. L. (2008). ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention. Cancer Epidemiol Biomarkers Prev, 17(8), 1884–1890. https://doi.org/10.1158/1055-9965.EPI-07-2696
Baker, Joseph C., Julie H. Ostrander, Siya Lem, Gloria Broadwater, Gregory R. Bean, Nicholas C. D’Amato, Vanessa K. Goldenberg, et al. “ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention.Cancer Epidemiol Biomarkers Prev 17, no. 8 (August 2008): 1884–90. https://doi.org/10.1158/1055-9965.EPI-07-2696.
Baker JC, Ostrander JH, Lem S, Broadwater G, Bean GR, D’Amato NC, et al. ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention. Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1884–90.
Baker, Joseph C., et al. “ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention.Cancer Epidemiol Biomarkers Prev, vol. 17, no. 8, Aug. 2008, pp. 1884–90. Pubmed, doi:10.1158/1055-9965.EPI-07-2696.
Baker JC, Ostrander JH, Lem S, Broadwater G, Bean GR, D’Amato NC, Goldenberg VK, Rowell C, Ibarra-Drendall C, Grant T, Pilie PG, Vasilatos SN, Troch MM, Scott V, Wilke LG, Paisie C, Rabiner SM, Torres-Hernandez A, Zalles CM, Seewaldt VL. ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention. Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1884–1890.

Published In

Cancer Epidemiol Biomarkers Prev

DOI

ISSN

1055-9965

Publication Date

August 2008

Volume

17

Issue

8

Start / End Page

1884 / 1890

Location

United States

Related Subject Headings

  • Time Factors
  • Tamoxifen
  • Promoter Regions, Genetic
  • Predictive Value of Tests
  • Polymerase Chain Reaction
  • Pilot Projects
  • Middle Aged
  • Immunohistochemistry
  • Humans
  • Female